True, although in Feb we were pre-covid and the share price was $340. So results in line with Feb report and guidance is a growth of NPAT of up to 8% for FY21. No reason why SP shouldn't be back at Feb levels then.
- Forums
- ASX - By Stock
- CSL
- Ann: CSL Results Announcement
Ann: CSL Results Announcement, page-14
-
- There are more pages in this discussion • 108 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$294.55 |
Change
-14.385(4.66%) |
Mkt cap ! $142.7B |
Open | High | Low | Value | Volume |
$300.03 | $301.28 | $291.47 | $284.6M | 958.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 169 | $294.53 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$294.56 | 38 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 133 | 294.240 |
11 | 176 | 294.230 |
7 | 57 | 294.220 |
2 | 5 | 294.190 |
5 | 82 | 294.180 |
Price($) | Vol. | No. |
---|---|---|
294.300 | 307 | 5 |
294.320 | 91 | 3 |
294.340 | 37 | 2 |
294.350 | 79 | 3 |
294.370 | 131 | 6 |
Last trade - 15.00pm 13/08/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online